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Abstract 
Background: Side effects of anti-epileptic drugs (AEDs) have not been adequately documented in 
trigeminal neuralgia (TN) and its variants. The aim of this observational cross-sectional study was to 
compare the A-B Neuropsychological Assessment Schedule (ABNAS), which measures cognitive side 
effects to the Adverse Events Profile (AEP), which looks at a broader range of side effects, and to 
investigate drug/dosage relationships with questionnaire scores to help determine a point at which a 
drug change would be indicated. Methods: 105 patients were recruited from a facial pain clinic, over a 
ten-month period. Self-complete questionnaire scores were compared between patients using different 
AEDs. Results: ABNAS score correlated well with AEP indicating that cognitive side effects were a 
significant burden. Toxic range on the ABNAS was estimated to occur when scores were > 43/72 (95% CI: 
37.4 to 48.6). Polytherapy is weakly associated with the higher scores. Oxcarbazepine dosage was found 
to linearly correlate with AEP and ABNAS scores, better than carbamazepine dosage. Memory alteration 
was least common with lamotrigine and oxcarbazepine, and there was less association between fatigue 
with oxcarbazepine/pregabalin. Conclusion: AEDs have significant side effects. The ABNAS questionnaire 
is a useful tool along with the AEP to recognize and monitor AEDs’ side effects and to help to adjust 
medications to optimal dosage.  
 
 
Main Body 
Introduction 
Trigeminal neuralgia (TN) is a condition characterized by recurrent unilateral episodes of electric shock-
like pain, lasting from a few seconds to minutes in the distribution of the trigeminal nerve (1). The pain 
is often provoked by a slight and innocuous stimulus, such as touch. TN is usually idiopathic, but can 
present as a consequence of vascular abnormalities, tumours and multiple sclerosis. 
There are other groups of conditions that are very similar to TN and in fact may be variants:  short 
unilateral neuralgiform headache with conjunctival redness and tearing (SUNCT) and short unilateral 
neuralgiform headache with autonomic features (SUNA) (2). 
First line drugs for idiopathic TN including SUNCT and SUNA are anti-epileptic drugs (AED), most 
commonly carbamazepine or oxcarbazepine (3). Alternative AEDs have been shown to be effective in 
TN, including lamotrigine  (4), gabapentin (5), pregabalin (6) and baclofen (7). SUNCT and SUNA seem to 
respond particularly well to lamotrigine (2).  Surgical treatment options for TN include microvascular 
decompression, stereotactic radiosurgery and percutaneous procedures such as glycerol rhizotomy, 
balloon compression, and radiofrequency thermocoagulation (8). 
Medical treatment is perceived by patients as being a safer option and associated with fewer 
complications which are usually reversible, in contrast to surgery, which can have significant irreversible 
complications. This leads most patients and clinicians to lean towards a conservative treatment (9). 
However, this choice is made with scarce clinical evidence.  One of the main reasons why patients opt 
for surgery is because of side effects from the AEDs (10) but little work has been done on this topic in 
TN. A qualitative survey conducted in 2001 (11) found that 100% of surveyed TN patients taking AEDs 
experienced side effects, including drowsiness and cognitive impairment, with a mean of three side 
effects per patient. 
A systematic review on carbamazepine performed in 2011 (12) reported that 40 – 60 % of patients 
would exhibit adverse events, including those mentioned above, as well as gastrointestinal symptoms, 
headaches, dry mouth or taste change, and mood changes. Other reviews highlight the same problem 
(13-18). However, none of these include information on how the adverse events were measured or 
whether they were quantified or compared between drugs in any way. A recent systematic review 
looking at adverse events assessment on trials of gabapentin and pregabalin in post-operative pain 
highlighted that adverse event assessment method was not described in 18% of studies, and 8/90  
studies did not report on adverse events at all (19). 
In the epilepsy literature, side effects of AEDs are often measured using the Liverpool Adverse Events 
Profile (AEP) (Supporting material Figure 1) (20) which has been psychometrically tested.  Ranging from 
19 – 76, a score of 45 or higher is indicative of toxicity (21). It has only recently been used to investigate 
side effects of AEDs in TN (22). 
However, the AEP does not enquire in depth on cognitive effects caused by the drugs, as its questions 
are mainly focused on other types of symptoms. The A-B Neuropsychological Assessment Schedule 
(ABNAS) (Supporting material Figure 2) includes questions on such symptoms (23, 24), but it has not 
been used in TN patients, nor has a cut-off score for toxic range been calculated yet.  
In this study, we aim to use the AEP and ABNAS to quantitatively investigate adverse effects of AEDs 
used in TN and related conditions, and postulate a toxic range cut-off for the ABNAS.  
 
Materials & Methods 
Participants 
Participants for this study were identified and consecutively recruited from a facial pain clinic in a 
London teaching hospital in the period between March and December 2015. Participants were asked to 
fill out an additional questionnaire, in addition to those that are routinely filled out during the follow up 
outpatient appointments. At this time point patients would have already been under treatment for at 
least three months, which is the interval between initial assessment and first follow-up. 
In order to be included, patients had to have a diagnosis of trigeminal neuralgic pain (TN, SUNA, or 
SUNCT), be treated with AEDs, be above 18 years of age, have sufficient cognitive function and English 
language skills to accurately complete the surveys, have had an MRI scan excluding focal lesions or 
multiple sclerosis, and finally, to have verbally consented to participate in the research study. Patients 
were excluded if they suffered from a medical condition severe enough to prevent them from 
completing the study, had a history of drug or alcohol abuse, had signs or symptoms of a central 
neurological disorder, if they were unwilling to perform cognitive function tests, and finally, if they were 
prescribed medication other than AEDs that could affect cognitive functions, such as anti-depressants.  
Although TN, SUNCT, and SUNA are considered to be different neurological conditions, there is evidence 
to support that they actually represent a variant of the same condition (25, 26), and ICD-11 
acknowledges overlap between them. Furthermore, it is known that pain conditions often change after 
their onset (27) and that patients can often move between these phenotypes over time. At the time of 
referral to this specialist pain clinic, all patients would have had TN as the predominant diagnosis and 
would be under initial treatment based on the initial TN diagnosis. However, at the time of follow up the 
phenotype may have changed to SUNCT or SUNA. We elected to include all of these patients in this 
study, as our primary interest was to study the side effect profile of AED medications in these pain 
conditions driven by trigeminal neuralgia. We have no reason to believe that AED side effects would 
differ significantly between these conditions. 
Measures 
The main measures of interest for this study were total scores of the AEP and ABNAS questionnaires. 
The order by which the two questionnaires were given to participants during their visit was alternated in 
a randomized manner. The ABNAS answers were assigned to categories of Slowing, Fatigue, Memory, 
Concentration, Motor and Language, as indicated by the questionnaire itself (23). Additionally, Brief Pain 
Inventory (BPI) – Facial (28, 29) and Hospital Anxiety and Depression Scale (HAD-A, HAD-D) (30) 
questionnaire scores were obtained as measures of pain relief, quality of life and mood. Mean score of 
the first four BPI questions was used as a primary measure for pain intensity as it is the standard 
measure used in most pain studies and the one used by the UK National Audit of Pain. Furthermore, 
these questions give a better estimate of pain severity in this case because TN is episodic. Pain scores 
were collected at the start of the outpatient review visit. Qualitative observations by participants and 
researchers alike were also obtained. The data was initially entered on an Excel spreadsheet on a secure 
server. The data was anonymized prior to analysis. 
Statistical analysis 
Statistical analysis was conducted using STATA 13 for Windows. Descriptive statistics were used to 
characterize the group’s demographics, symptomatology, medications used, and questionnaire scores. 
As drug blood levels were not available for this study, indirect means were used to calculate a possible 
toxic range cut-off score for ABNAS. The toxic range cut-off point of the AEP was used to divide the 
study participants into two groups. The mean, median, standard deviation, and interquartile ranges of 
the ABNAS score in the toxic range group were used to approximate a similar cut-off score for ABNAS. 
For drug and dosage-specific analyses, a comparison of AEP, ABNAS, BPI, HAD-A, and HAD-D scores was 
conducted between single- and multi-drug therapy subgroups using appropriate group-wise 
comparisons where necessary, either t-tests or Mann-Whitney U tests depending on the distribution of 
the measure of interest, in each group or subgroup compared. For the BPI analysis, different mean 
scores were calculated for each group of BPI questions: Mean pain intensity (Q1-Q4), mean general QOL 
Score (Q5a-Q5g), and mean facial score (Q5h-Q5n). Relationships between medication dosage and 
questionnaire scores were investigated using scatterplots and estimated correlation coefficients, 
although the study wasn't powered to assess the statistical significance, if any, of such relationships. 
 
Results 
Group demographics and questionnaire statistics 
As a result of the above mentioned criteria, 105 patients were selected to be part of the study group. 
The demographics of this group and group statistics of the measures of interest are listed in Table 1. The 
majority of these patients had a diagnosis of trigeminal neuralgia (n=75), while the rest had other 
variants of neuropathic pain, such as SUNA (n=13), trigeminal neuralgia with concomitant pain (n=6), or 
in various combinations (n=11). In terms of medication, 78 patients were on monotherapy, while 27 
were on polytherapy. The vast majority were treated with oxcarbazepine, carbamazepine, or 
lamotrigine, as shown in detail in Table 2 (Supporting material Figure 3). 
 
Total (N=105)  
Mean (SD) 
Female (N = 80) 
Mean (SD) 
Male (N = 25) 
Mean (SD) 
Age 62.2 (11.5) 61.2 (11.5) 65.6 (11.2) 
AEP total 
(19-76) 
38.6 (10.7) 
(n=104) 
38.9 (10.9) 
(n=79) 
37.2 (10.4) 
(n=25) 
ABNAS total 
(0-72) 
27.8 (19) 
(n=98) 
26.2 (18.5) 
(n=75) 
33.3 (20) 
(n=23) 
BPI mean pain intensity 
Mean 
(0-10) 
3.3 (2.5) 
(n=95) 
3.3 (2.5) 
(n=73) 
3.3 (2.7) 
(n=22) 
BPI General QOL Score 
Mean (questions 5a-5g)  
(0-10) 
3.4 (3.0) 
(n=92) 
3.4 (3.0) 
(n=71) 
3.5 (3.1) 
(n=21) 
BPI “Facial” Score Mean 
(questions 5h-5n) (0-10) 
4.5 (3.3) 
(n=93) 
4.7 (3.3) 
(n=71) 
3.8 (3.3) 
(n=22) 
HAD-A 
(0-21) 
8.1 (4.8) 
(n=102) 
8.1 (4.9) 
(n=77) 
8 (4.6) 
(n=25) 
HAD-D 
(0-21) 
6.3 (4.4) 
(n=102) 
6.1 (4.4) 
(n=77) 
6.7 (4.7) 
(n=25) 
 
Table 1. Group demographics and questionnaire statistics. BPI: Brief Pain Inventory, QOL: Quality of Life, HAD-A, HAD-D: 
Hospital Anxiety and Depression scale. 
  Monotherapy Polytherapy Total 
 N Dose range 
(mg) 
Mean dose 
(mg) (SD) 
N Dose range 
(mg) 
Mean dose 
(mg) (SD) 
N Dose 
range 
(mg) 
Mean dose 
(mg) (SD) 
CBZ 20 300-1800 820 (470) 8 400-1400 787 (422) 28 300-1800 810 (450) 
OXC 30 70-1800 819 (457) 18 75-3600 1190 (894) 48 70-3600 958 (671) 
LAM 9 25-800 311 (221) 19 50-1400 360 (311) 28 25-1400 344 (282) 
GBP 12 200-3600 1875 
(1332) 
4 300-1800 1125 (665) 16 200-3600 1687 
(1226) 
PGB 7 150-600 353 (182) 4 150-700 437 (256) 11 150-700 384 (203) 
 
Table 2. Group demographics and questionnaire statistics. BPI: Brief Pain Inventory, QOL: Quality of Life, HAD-A, HAD-D: 
Hospital Anxiety and Depression scale. 
ABNAS toxic range cut-off score 
The distributions of AEP and ABNAS scores in the entire patient group are shown in the histograms and 
boxplots below (Fig. 1). Scores have been converted to a 100-point scale, with zero and 100 being the 
lowest and highest possible scores of each questionnaire respectively. The histograms suggest that the 
distributions of both the AEP and ABNAS scores are not symmetrical. The scatterplot (lower right-hand 
Fig. 1) demonstrates that, as expected, there is a strong linear correlation between ABNAS and AEP total 
scores (Pearson’s correlation coefficient: 0.67). 
 Figure 1. Histograms and boxplots of AEP and ABNAS scores in the entire patient group. Scores for these graphs have been 
converted to a 0-100 scale, with 0 and 100 being the lowest and highest possible scores in each test, respectively. Lower right 
hand 
Out of the 104 patients that had filled in the AEP questionnaire, 30 fell into the toxic range, as defined 
by an AEP score higher than 45. In order to approximate a similar cut-off for the ABNAS questionnaire, 
we calculated the mean and standard error of the ABNAS score in this patient subgroup. We calculated 
the mean and corresponding 95% confidence interval as 43 (95% CI: 37.4 to 48.6). Fig. 2 shows boxplots 
of the ABNAS score, stratified by AEP score category (AEP 45 and AEP>45). A Mann-Whitney U test 
suggested a significant difference in ABNAS score between these groups (P-value < 0.001).  
 Figure 2. Boxplot of ABNAS total score in the two subgroups as defined by the AEP neurotoxicity cut-off score. (*Mann-Whitney 
U test) 
 
ABNAS Subcategories, polytherapy, and dosage correlations 
In terms of ABNAS sub-categories, the questions with highest scores were those in the categories of 
memory and cognition, while motor complaints were the least common (Fig. 3). It seems that 
distributions of score types are similar for carbamazepine and oxcarbazepine, with oxcarbazepine 
exhibiting lower scores in all categories (Fig. 3b). However, there is more variation for lamotrigine and 
gabapentin (although we note the small number of patients on each of these drugs). Comparing single 
and multiple drug groups (Fig. 3c) it looks like there might be lower scores in motor, and perhaps 
language, categories for the patients on single drugs compare to those on multiple drugs.  
 Figure 3. a) Boxplot of ABNAS subcategories scores in the entire patient group, converted to a 100-point scale (0 and 100 being 
the lowest and highest possible scores in each subcategory respectively. b) Boxplots of ABNAS subcategories for single drug gr 
When comparing patients that were under a single drug medication with those taking two or more 
drugs, questionnaire scores tended to be lower for the single-drug group, a difference which was 
statistically significant in AEP total score (p=0.04), but only a trend in ABNAS total score (p=0.11)(two-
sample t-test)(Supporting material Figure 4).  18 out of 78 monotherapy participants, and 12 out of 27 
polytherapy participants were in the toxic dose range as defined by their AEP score. Νo statistically 
significant difference was evident when comparing these groups on BPI mean pain intensity (BPI 
questions 1-4). However, AEP and ABNAS total scores correlated positively with BPI mean pain intensity 
with a Spearman’s rho of 0.4555 (p<0.0001) and 0.3372 (p=0.0009) respectively. In the polytherapy 
group, 12 patients had a mean BPI Pain score (questions 1-4) higher than 4, while 14 patients were 
below 4. One patient had not completed the BPI questionnaire. 
Figure 4 shows plots of AEP, ABNAS and BPI (questions 1-4) scores versus drug dose for carbamazepine 
and oxcarbazepine. There are apparent positive linear correlations between AEP, ABNAS and BPI score 
and oxcarbazepine dose (right-side plots of Figures 4a, 4b)(Spearman’s correlation coefficients: 0.54 for 
AEP, 0.46 for ABNAS, 0.18 for BPI). These linear correlations are much less apparent between 
AEP/ABNAS/BPI and carbamazepine dose (left-side plots of Fig. 4a, 4b)(Spearman’s correlation 
coefficients: 0.24 for AEP, 0.13 for ABNAS, 0.06 for BPI). This could indicate some dose related side 
effects for oxcarbazepine. The apparent relationships and the disparity between the two drugs were still 
evident when using only participants on monotherapy.  
 Figure 4. a) Scatterplots of questionnaire total scores against dosage of CBZ and OXC, with an approximated linear fit and 95% 
CI. Includes both monotherapy and polytherapy patients. 
Qualitative comments 
During the study patients were asked to offer comments on their opinion regarding all three 
questionnaires. Of 47 patients who commented, 23% preferred the AEP questionnaire, 66% the ABNAS 
and 11% had no preference. Patients who preferred the ABNAS questionnaire found the questions more 
specific, so they felt sure they were interpreting them correctly. Several patients remarked that despite 
there being more questions in ABNAS, the overall time taken to fill in the entire questionnaire was 
shorter as they found that AEP had more general categories in comparison to ABNAS. Another 
difference noted by patients was that they felt the ABNAS questions purely allowed them to note their 
cognitive symptoms while the AEP had a more physical focus. Several patients commented that they 
found that cognitive symptoms were the most frequently experienced side effect, so they found the 
ABNAS questionnaire overall more relevant. However, this symptomatology could arise both due to the 
severity of the pain itself as well as anxiety and depression (30). Finally, the omission of any question 
addressing double vision in the ABNAS was also noted. 
Regarding both questionnaires, in spite of patients being explicitly reminded to base their answers 
subjectively on medication adverse effects, several said they found it difficult to distinguish drug adverse 
effects with experiences caused by pain or concurrent medical conditions. Patients on multiple 
medications in particular had greater difficulty in completing the questionnaires. In one extreme case, a 
patient on 13 drugs was unable to complete any questions as she found it impossible to distinguish the 
effects of only her trigeminal neuralgia medication. 
Patients responded positively to the aesthetics of the questionnaire and found both simple to interpret. 
Most patients did not have preference between a landscape or portrait questionnaire layout, though of 
the 17 that did state a preference, only one preferred a landscape setup. Reasons behind preferring a 
portrait layout were due to a dislike for visually scanning longer lines of text on the landscape layout. 
 
Discussion 
In the literature, guidelines or clinical protocols, major emphasis is put on drug efficacy and indications 
for their use, yet patient quality of life is often compromised by side effects. On the other hand, 
clinicians are provided with very little support when patients experience intolerability to a specific drug 
or treatment protocol. Very few randomized controlled trials use validated questionnaires of adverse 
events and the tendency is only to report significant ones (19). 
This study shows that all current AEDs most commonly used in the management of TN and associated 
variants result in side effects. The most prominent ones are cognitive. We propose that ABNAS comes 
out as a comprehensive questionnaire in the clinical setting, when applied to TN and related patients. It 
supplements HAD-A and HAD-D to measure patients’ quality of life and tolerability of treatment. 
However, these results alone are not enough to yet define a specific toxic range cut-off point, and more 
validation is required. 
Some interesting findings arose when comparing different drugs’ side effect profiles, the impact of each 
one’s increase with dosage, and with polytherapy. Qualitatively, it seems that oxcarbazepine is better 
tolerated than carbamazepine in all categories of side effects. However, an increase in oxcarbazepine 
dosage was less tolerated, and correlated with higher side-effect scores. This was not the case with 
carbamazepine. Data was collected at least three months after treatment onset, so autoinduction of 
carbamazepine metabolism could be a possible reason for this observation, as it is not known to occur 
with oxcarbazepine. However, oxcarbazepine metabolites are very similar, and it is possible that this 
study’s sample size is too small to pick up on such changes and subtle differences. Furthermore, without 
data on serum carbamazepine levels, which are unreliable, it was not possible to test this hypothesis in 
this study. One possible application of this observation could be that perhaps if a patient under 
carbamazepine treatment can tolerate its side effects, an increase in dosage could be attempted, with a 
potential for side effects to remain at the same level. The same cannot be easily said about 
oxcarbazepine based on our results.  
In terms of side effect sub-groups, lamotrigine and oxcarbazepine seem to have the lowest negative 
impact on memory. If fatigue is a problem, oxcarbazepine and pregabalin may prove a better option. 
Interestingly in 528 patients using pregabalin for anxiety or panic disorders, the major side effects were 
dizziness, insomnia for 9% and somnolence in 8.5% (31). These were not measured with a questionnaire 
but through self-reporting, with 77% experienced at least one side effect. Finally, our results suggest 
that when comparing multiple medications with a single agent, there is a tendency for the side effects to 
increase, particularly in the subcategories of concentration, motor coordination, and language, but with 
low statistical significance.   
As these self-complete questionnaires can be filled out in the waiting room prior to consultation, they 
can provide a better, patient-centered management without necessarily expecting an increase in 
consultation time. They can lead to further laboratory investigations, be used to monitor side effects 
over time, and determine which drug and dosage is better suited for each patient. Potentially they could 
prompt to a switch to other drugs, and/or initiate polytherapy or referral for neurosurgical therapies. 
Limitations 
The nature of self-reporting is one of the main limitations of this study, as is often the case with 
questionnaire research. Pain, well known to being a subjective and therefore complex experience, often 
influences the reported side effects of medications. Some patients do find difficult to differentiate 
between symptoms linked with pain of underlying disease, mood, and or medications’ side effects, as is 
evident by the correlation we found between AEP/ABNAS total scores and BPI mean pain intensity. For 
example, “trouble in their mouth”, could be to both the condition itself as well as development of the 
side effect. Depression and anxiety are also known to influence response to treatment and can 
confound results. Finally, the sample population is lacking in homogeneity. Future studies in the topic 
will greatly benefit from recruiting a more homogeneous group of patients. 
Future directions 
Subjectively, our dataset has shown the importance of assessing cognitive functions in patients who are 
often performing highly complex tasks in their demanding professional lives. It would therefore be 
important to also develop objective tests using computer-based programs to measure these effects e.g. 
the Kinematic Assessment Tool (KAT). The KAT is a computerized battery of psychometric tests. 
Information is acquired via a touch-sensitive screen and in addition may also pick up further side effects 
such as unsteadiness or tremor (32). Furthermore, the ABNAS questionnaire would also be a useful tool 
in future studies comparing side effect profiles of centrally and peripherally acting medications.  
Conclusion 
The ABNAS questionnaire can be a useful tool for monitoring side effects and personalizing treatment, 
as it depicts patients’ side effect profile in more detail, and is better focused on common cognitive 
adverse effects than the questionnaires commonly used today. The present study attempted to quantify 
side effects more objectively so that clinicians were alerted to switch pharmacotherapy from one agent 
to another or even to consider surgical solutions as last resort. Polytherapy showed increase in both 
number and intensity of side effects. Although CBZ and OXC seem to share similar side effect profiles, 
patients under OXC tended to report less side effects at low dose. However, these seemed to be dose-
dependent, than CBZ. ABNAS data also allowed for a more accurate depiction of the types of side effects 
associated with each drug, through subcategory scores. Evidently, more research is needed to further 
validate ABNAS total score and sub-scores as measures of interest, but it could prove advantageous over 
AEP in similar patient groups to the present. Future research could also incorporate ABNAS and data 
similar to this study to investigate side effects and quality of life comparing medical and surgical 
treatments. 
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Supporting material 
Supporting material Figure 1. The AEP questionnaire
 
Supporting material Figure 2. The ABNAS questionnaire
 
Supporting material Figure 3. Bar chart indicating number of patients that were under 
medication with each drug. Darker hue indicates monotheraphy, lighter hue indicates part of 
polytherapy. OXC: Oxcarbazepine CBZ: Carbamazepine LAM: Lamotrigine GBP: Gabapentin PGB: 
Pregabalin LEV: Levetiracetam LAC: Lacosamide
 
Supporting material Figure 4. Box-plot Comparison of questionnaire scores between subgroups 
of patients under single and multiple drug regimens. (* two-sample t-test)
 
 
 
